Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


Ibrutinib (Imbruvica, trade name: Yike) is the world’s first BTK inhibitor approved for marketing. In November 2013, ibrutinib capsules (70 mg and 140 mg) were approved by the FDA for the treatment of mantle cell lymphoma.